OBJECTIVE

Zuojin pill (ZJP) is used as the classical prescription for a wide variety of digestive diseases. However, there is a lack of direct evidence for its use in the treatment of chronic nonatrophic gastritis (CNG). In particular, there is a lack of rigorous trials of randomized controlled designs. In this study, a randomized active-controlled clinical trial was performed to verify the efficacy and safety of ZJP in detail.

METHODS

Patients with CNG were divided into the ZJP group and the Marzulene-S granule group. Patients were enrolled from September 2019 to February 2021 (ChiCTR2000040549). Endoscopy and histology scores were evaluated as the primary outcome measure. The positive rate and the disappearance rate of symptoms were also measured to reflect the outcomes. Finally, adverse events were also calculated as the index of safety.

RESULTS

A total of 68 eligible patients were enrolled in this trial and randomly divided into two groups with baseline comparability. ZJP was able to improve the red plaques as well as bile reflux scores compared with Marzulene-S granule (=0.043 and =0.019, respectively). Moreover, it also remarkably alleviated the active chronic inflammation score (=0.043). However, there was no difference between the positivity rate (=0.752). The symptom scores of abdominal distension (=0.004), belching (=0.010), and loss of appetite (=0.019) were alleviated by ZJP, but nausea and vomiting were not (=0.616). ZJP can also be considered safe with no obvious adverse effects.

CONCLUSION

ZJP might decrease mucosal injury and alleviate symptoms in CNG. In addition, more large-scale clinical trials should be carried out to further confirm its clinical efficacy and safety.